MFT: ARevolutionizingGeneticTesting (G123263)

Target Name: MTFMT

NCBI ID: G123263

MTFMT

MFT: ARevolutionizingGeneticTesting

Mount Frequency Tuning (MFT) is a genetic testing technology based on the principle of frequency tuning, proposed by researchers at the Broad Institute in the United States. This technology uses high-throughput sequencing technology to quantitatively analyze gene expression levels in cells or tissues, helping researchers understand differences in gene expression in tissues and thereby guiding disease diagnosis and treatment.

MFT is a new type of genetic testing technology that has higher sensitivity and faster detection speed than traditional genetic testing technology. By analyzing high-throughput sequencing data, MFT can detect gene expression levels in individual cells or tissues, allowing researchers to more accurately understand differences in gene expression in tissues.

The basic principle of MFT technology is to process high-throughput sequencing signals through the frequency tuning principle to detect gene expression levels. By frequency tuning the high-throughput sequencing signal, the MFT team can obtain a new signal that is more responsive and has a higher signal-to-noise ratio than the original signal. Through this method, MFT can detect gene expression levels in individual cells or tissues, thereby providing an important basis for disease diagnosis and treatment.

MFT technology is widely used in disease diagnosis and treatment. For example, MFT can be used in the diagnosis and treatment of cancer.

Protein Name: Mitochondrial Methionyl-tRNA Formyltransferase

Functions: Methionyl-tRNA formyltransferase that formylates methionyl-tRNA in mitochondria and is crucial for translation initiation

The "MTFMT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MTFMT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets